SNY Quote, Financials, Valuation and Earnings

GSK PLC has a net margin of 19.88% compared to Sanofi SA's net margin of -0.72%. Sanofi SA's return on equity of 5.8% beat GSK PLC's return on equity of 18.89%.

Sanofi SA has a consensus price target of $63.06, signalling upside risk potential of 32.1%. On the other hand GSK PLC has an analysts' consensus of $42.93 which suggests that it could grow by 34.15%. Given that GSK PLC has higher upside potential than Sanofi SA, analysts believe GSK PLC is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.585, which suggesting that the stock is 41.492% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.349%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 8.25%. GSK PLC offers a yield of 4.66% to investors and pays a quarterly dividend of $0.39 per share. Sanofi SA pays 82.48% of its earnings as a dividend. GSK PLC pays out 45.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $15.6B, which are larger than GSK PLC quarterly revenues of $10.4B. Sanofi SA's net income of $3.1B is higher than GSK PLC's net income of -$75.5M. Notably, Sanofi SA's price-to-earnings ratio is 24.19x while GSK PLC's PE ratio is 21.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.25x versus 1.74x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 19.88% compared to Sanofi SA's net margin of 0.7%. Sanofi SA's return on equity of 5.8% beat Moderna's return on equity of -17.44%.

Sanofi SA has a consensus price target of $63.06, signalling upside risk potential of 32.1%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 88.34%. Given that Moderna has higher upside potential than Sanofi SA, analysts believe Moderna is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.585, which suggesting that the stock is 41.492% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 8.25%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 82.48% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $15.6B, which are larger than Moderna quarterly revenues of $1.9B. Sanofi SA's net income of $3.1B is higher than Moderna's net income of $13M. Notably, Sanofi SA's price-to-earnings ratio is 24.19x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.25x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 19.88% compared to Sanofi SA's net margin of -143.53%. Sanofi SA's return on equity of 5.8% beat Novavax's return on equity of --.

Sanofi SA has a consensus price target of $63.06, signalling upside risk potential of 32.1%. On the other hand Novavax has an analysts' consensus of $16.00 which suggests that it could grow by 83.59%. Given that Novavax has higher upside potential than Sanofi SA, analysts believe Novavax is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.585, which suggesting that the stock is 41.492% less volatile than S&P 500. In comparison Novavax has a beta of 2.017, suggesting its more volatile than the S&P 500 by 101.749%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 8.25%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 82.48% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $15.6B, which are larger than Novavax quarterly revenues of $84.5M. Sanofi SA's net income of $3.1B is higher than Novavax's net income of -$121.3M. Notably, Sanofi SA's price-to-earnings ratio is 24.19x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.25x versus 1.52x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 19.88% compared to Sanofi SA's net margin of 36.03%. Sanofi SA's return on equity of 5.8% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Sanofi SA has a consensus price target of $63.06, signalling upside risk potential of 32.1%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 50.04%. Given that Regeneron Pharmaceuticals has higher upside potential than Sanofi SA, analysts believe Regeneron Pharmaceuticals is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.585, which suggesting that the stock is 41.492% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 8.25%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 82.48% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $15.6B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Sanofi SA's net income of $3.1B is higher than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Sanofi SA's price-to-earnings ratio is 24.19x while Regeneron Pharmaceuticals's PE ratio is 17.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.25x versus 5.83x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.